Abstracts differences to be much higher than median differences. Regression analysis explained about 40% of the cost variance and indicated no significant total cost differences between therapies. Clinically evaluable sample results were qualitatively similar to the ITT sample. CONCLU-SION: Substantial variation in hospital costs in this moderately large multinational Phase-3 trial does not allow definitive conclusions regarding whether the length of stay differences seen earlier result in total treatment cost differences. In future research, combining data with other similar trials may allow for more precise point estimates of cost differences.
OBJECTIVE:
A pharmacoeconomic analysis was carried out comparing the efficiency of two treatment options for acute exacerbation of chronic bronchitis (AECB): Telithromycin and Cefuroxime-axetil. METHODS: Retrospective analysis using a decision tree model. The efficacy of the 2 treatment options was estimated from a randomised, double-blind clinical trial, in which 800 mg/day (5 days) of Telithromycin was compared to 1,000 mg/day (10 days) of Cefuroxime-axetil in patients with AECB (140 and 142 respectively). The utilisation of resources was estimated from the clinical trial and Spanish sources, and the unit costs from a Spanish health costs database. Costs were evaluated for the acquisition of antibiotic treatments, change of antibiotic due to therapeutic failure, hospital admissions, adverse reactions treatment, primary care visits, tests and indirect costs (working days lost). The model was validated by a panel of Spanish clinical experts. RESULTS: As the clinical trial was designed to show equivalence, there were no significant differences in efficacy between the treatment options (clinical cure rate 86.4% and 83.1% respectively), and a cost minimisation analysis was performed. In the base case, the average cost of the disease per patient was €174.83 with Telithromycin and €194.68 with Cefuroxime-axetil (a difference of €19.85). The results were stable in the sensitivity analysis, with differences favourable to Telithromycin ranging between €18.04 and €22.25. CONCLUSIONS: Telithromycin results in a cost saving of up to €22 per patient with AECB compared to Cefuroxime-axetil. 
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FIVE-YEAR BUDGET IMPACT AND LIFETIME COST EFFECTIVENESS OF A LOPINAVIR/RITONAVIR (LVP/r) VS. A NELFINAVIR (NFV) CONTAINING REGIMEN FOR TREATMENT-NAÏVE PATIENTS
OBJECTIVES:
Clinical trials of antiretroviral (ARV) regimens are too short to allow a long-term assessment of economic and quality of life differences for competing regimens. However, surrogate marker data from ARV trials used in a long-term mathematical model that incorporates epidemiologic and economic data, and current treatment patterns, can be used to estimate long-term costs and outcome differences. This study compares longterm health outcomes and cost effectiveness of LVP/r vs. NFV regimens in treatment-naïve patients. METHODS: We developed a new generation three-compartment Markov model with a combination of viral load and CD4 count as surrogate markers compared to the previous generation model using only CD4 count as a surrogate marker. The model applied epidemiologic data from 5,000 patients on HAART therapy, cost data from 2,000 U.S. Medicaid patients, and quality of life data from 21,000 HIV-patient responses to the EQ5D. The model's predictive ability was tested against published HAART study data, and on data from 1,456 HIV U.S. patients in 70 primary care practices. Into this validated model we inserted the study VL and CD4 count data (ITT missing = fail) from the 48-week analysis of the ABT-M98-863 clinical trial. RESULTS: The model estimated a $4,011 per patient cost savings in favor of the LVP/r regimen, when budget impacts were compared over the first 5 years. The incremental cost effectiveness ratio was $3,423/QALY for LVP/r vs. NFV, and an improvement in median survival of 24 QALYs for a cohort of 100 patients was found. This cost effectiveness ratio is comparable to values for generic blood pressure control medications. The results were robust under sensitivity analysis. CON-CLUSIONS: Under the model assumptions, use of LVP/r in the first ARV regimen, as compared to NFV, leads to cost savings over the first 5 years of therapy, and appears to be cost effective over the patients lifetime.
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COST-CONSEQUENCE COMPARISON OF LOPINAVIR/RITONAVIR (LPV/r) VS. NELFINAVIR (NFV) THERAPY IN TREATING ANTIRETROVIRAL NAÏVE HIV PATIENTS USING CLINICAL TRIAL DATA
Luo MP, Boggs B, Bernstein B, Sun E, Ashraf T Abbott Laboratories, Abbott Park, IL, USA OBJECTIVES: To evaluate the cost-consequence of LVP/r compared with NFV in treating antiretroviral (ARV) naïve HIV patients. METHODS: A decision tree model was developed based on the Department of Health and Human Services (DHHS) guidelines and the survey of HIV treating physicians. The model was used to reanalyze the ABT-M98-863 pivotal clinical trial data submitted to FDA/EMEA, a randomized phase III study of LVP/r vs. NFV plus d4T/3TC in 653 ARV naïve HIV patients. Therapeutic failure was defined as 2 successive (4 weeks apart) viral loads (VL) >400 copies/ml. In the model, therapeutic responders continued with their initial treatment, while failures received drug resistance tests and additional monitoring. Failures who developed drug resistance switched to a 2PIs + 2NRTIs regimen, while others stayed in the PI + 2NRTIs regimen class. A maximum of 1 therapy switch was allowed. Failures were at risk for AIDS events determined by CD4 count and VL. Cost analysis in 2002 U.S. dollars was performed from a third party payer's perspective. One-way sensitivity analysis tested the robustness of the assumptions. RESULTS: The model showed that after 60 weeks of therapy, compared to NFV, 22.1% more patients who started on LVP/r remained as responders, yielding a net savings of $1,454.14 per patient. Reduced treatment costs for therapy failures and AIDS events were the main contributions to the net savings. In sensitivity analysis, when the VL threshold for therapeutic failure was set at 50, 1,000, or 5,000 copies/ml, cost savings remained at $1,520.15, $1,233.52, and $1,062.26, respectively. When the regimen for all failures was changed to 2PI + 2NRTIs, PI + NNRTI + 2NRTIs, or PI + 2NRTIs, the estimated savings changed to $2,704.38, $1,928.46, and $838.35, respectively. CONCLUSIONS: The results suggest that if treatment guidelines are applied in the management of ARV naïve HIV patients, LVP/r may reduce the number of patients switching regimens and consequently may decrease total costs when compared with NFV.
